Table 2.

Impact of CRISPR base editing on parameters related to atherosclerosis table generated from data in ref. [31].

Parameter	Model	Number of Experimental Animals	Effect
Splice site editing	Human hepatocytes in vitro	NA	>60% splice site editing achieved at splice site
PCSK9 expression	Human hepatocytes in vitro	NA	PCSK9 expression reduced by 55%
Splice site editing	Mouse in vivo	4–5	A 70% liver base editing of the splice site
Splice site editing	Cynomolgus monkeys in vivo	2–3	A 63% base-editing frequency of the PCSK9 splice-site after two weeks
PCSK9 expression	Cynomolgus monkeys in vivo	2–3	A 81% reduction in blood PCSK9
LDL-C	Cynomolgus monkeys in vivo	2–3	A 65% reduction in blood LDL-C